Galovan Scott Michael 4/A

What Happened
Scott Galovan, Chief Financial Officer of Avanos Medical, received equity awards on March 13, 2026: 29,481 time‑based restricted share units (TRSUs) and 69,630 additional awards reported as derivative TRSUs. Both awards were granted at $0.00 (no cash paid). The TRSUs are economic equivalents of one share of Avanos common stock but are subject to vesting schedules and therefore do not represent immediately tradable shares.

Key Details

• Transaction date: March 13, 2026; both grants reported at $0.00 per share (no purchase price).
• Award amounts: 29,481 TRSUs (F1) and 69,630 derivative TRSUs (F2).
• Vesting: 29,481 TRSUs vest 1/3 on Mar 13 of 2027, 2028 and 2029 (F1). The 69,630 award vests 30% on Mar 13, 2027, 30% on Mar 13, 2028 and 40% on Mar 13, 2029 (F2).
• Shares owned after transaction: Not disclosed in this amended filing.
• Filing status: This is an amended Form 4/A correcting a prior Form 4/A (the original Form 4 filed Mar 17, 2026 reportedly had the correct option counts). The amendment clarifies an earlier reporting error that had incorrectly added to the number of stock options reported.

Context
These are compensation awards (time‑based restricted share units) rather than open‑market purchases or sales. TRSUs are derivative rights that convert to shares only as they vest, so they do not represent immediate cash proceeds or market sales. Amended filings like this correct reporting details and do not by themselves indicate a change in the insider’s view of the company.